Raman Prakash 4

What Happened
Raman Prakash, a director of Black Diamond Therapeutics, was granted a derivative award covering 40,000 shares on June 26, 2026. The Form 4 reports $0.00 as the acquisition price (no cash paid) — this is an award/option-type grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-29 (filed in a timely manner).
• Instrument: derivative award reported as acquisition (Code A) for 40,000 shares; consideration reported $0.00.
• Vesting: Award vests and becomes exercisable in full upon the earlier of (i) June 26, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing.
• No 10b5-1 plan, tax-withholding, or cashless exercise noted in the filing.

Context
This was a compensation-style derivative grant to a director (not a purchase or sale). Such awards are common for board compensation and do not indicate an immediate buy or sell of stock; the recipient must remain in service until vesting to exercise the award.